NO20033785L - Farmasöytisk formulering - Google Patents

Farmasöytisk formulering

Info

Publication number: NO20033785L
Authority: NO; Norway
Prior art keywords: pharmaceutical formulation; formulation; pharmaceutical
Prior art date: 2001-02-27

Application number

NO20033785A

Other languages

English (en)

Other versions

NO20033785D0 (no

Inventor

Nicola Bateman

Julie Cahill

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2003-08-26

Publication date

2003-10-24

2001-02-27 Priority claimed from GB0104749A external-priority patent/GB2372444A/en

2001-07-19 Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx

2003-08-26 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-08-26 Publication of NO20033785D0 publication Critical patent/NO20033785D0/no

2003-10-24 Publication of NO20033785L publication Critical patent/NO20033785L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20033785A 2001-02-27 2003-08-26 Farmasöytisk formulering NO20033785L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0104749A GB2372444A (en)	2001-02-27	2001-02-27	A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv)	2001-07-19	2001-07-19	Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (en)	2001-02-27	2002-02-22	Pharmaceutical formulation comprising bicalutamide

Publications (2)

Publication Number	Publication Date
NO20033785D0 NO20033785D0 (no)	2003-08-26
NO20033785L true NO20033785L (no)	2003-10-24

Family

ID=26245766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033785A NO20033785L (no)	2001-02-27	2003-08-26	Farmasöytisk formulering

Country Status (22)

Country	Link
US (1)	US20040067257A1 (no)
EP (1)	EP1368001B1 (no)
JP (2)	JP3548566B2 (no)
KR (1)	KR20030077042A (no)
CN (1)	CN1503662A (no)
AR (1)	AR032912A1 (no)
AT (1)	ATE307571T1 (no)
CA (1)	CA2439366A1 (no)
CZ (1)	CZ20032225A3 (no)
DE (1)	DE60206889T2 (no)
EE (1)	EE200300416A (no)
HU (1)	HUP0302847A3 (no)
IL (1)	IL157389A0 (no)
IS (1)	IS6915A (no)
MX (1)	MXPA03007641A (no)
NO (1)	NO20033785L (no)
NZ (1)	NZ527532A (no)
PL (1)	PL365746A1 (no)
RU (1)	RU2003128971A (no)
SK (1)	SK10722003A3 (no)
UY (1)	UY27186A1 (no)
WO (1)	WO2002067893A2 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
TWI355276B (en) *	2003-01-14	2012-01-01	Akira Tsuji	Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
JP4982084B2 (ja) *	2004-02-09	2012-07-25	株式会社サンギ	抗腫瘍剤
KR100539706B1 (ko) *	2005-01-25	2005-12-28	지엘팜텍 주식회사	타크로리무스 및 장용성 고분자를 함유하는 고체분산체
JP2008531531A (ja) *	2005-02-23	2008-08-14	アストラゼネカアクチボラグ	方法
EP1872798B1 (en)	2005-04-06	2013-06-05	Kabushiki Kaisha Sangi	Intestinal absorptive anti-tumor agent
US7785629B2 (en) *	2005-06-21	2010-08-31	Helm Ag	Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) *	2006-06-16	2012-10-17	トーアエイヨー株式会社	腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) *	2006-08-17	2008-02-21	Gawande Rahul S	Bicalutamide compositions
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
BRPI0814423B1 (pt)	2007-07-17	2022-04-19	Plexxikon, Inc	Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
JPWO2009038112A1 (ja)	2007-09-21	2011-01-06	塩野義製薬株式会社	Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5204452B2 (ja) *	2007-10-02	2013-06-05	日医工株式会社	ビカルタミド含有製剤
EP2219624A2 (en) *	2007-11-08	2010-08-25	Glaxo Group Limited	Pharmaceutical formulations
MX2011008303A (es)	2009-04-03	2011-11-29	Plexxikon Inc	Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas.
CN101987086B (zh) *	2009-08-03	2012-07-18	北京化工大学	一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
BR112012012156A2 (pt)	2009-11-06	2015-09-08	Plexxikon Inc	compostos e métodos para modulação de cinase, e indicações para esta
EP2512448B1 (en)	2009-12-18	2016-07-06	Endotis Pharma	Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) *	2010-12-20	2013-11-20	西安力邦医药科技有限责任公司	拉米夫定固体分散体、其制备方法、药物组合物和用途
AU2012214762B2 (en)	2011-02-07	2015-08-13	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
WO2014043208A1 (en)	2012-09-11	2014-03-20	Medivation Prostate Therapeutics, Inc.	Formulations of enzalutamide
EP3193877A4 (en) *	2014-08-07	2018-04-04	Pharmacyclics LLC	Novel formulations of a bruton's tyrosine kinase inhibitor
CA2969675C (en)	2014-12-05	2023-06-06	Aragon Pharmaceuticals, Inc.	Anticancer compositions
BR112017011788A2 (pt)	2014-12-05	2017-12-26	Aragon Pharmaceuticals Inc	composições anticâncer
US11266630B2 (en) *	2016-12-15	2022-03-08	Hua Medicine (Shanghai) Ltd.	Oral preparation of glucokinase activator and preparation method therefor
EA202192793A1 (ru)	2019-04-11	2022-01-12	Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи	Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
GB2584341B (en) *	2019-05-31	2023-03-01	Gw Res Ltd	Cannabinoid formulations
US11173291B2 (en) *	2020-03-20	2021-11-16	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery
US11344526B2 (en)	2020-03-20	2022-05-31	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU88769I2 (fr) *	1982-07-23	1996-11-05	Zeneca Ltd	Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
JP2527107B2 (ja) *	1991-04-16	1996-08-21	日本新薬株式会社	固体分散体の製造方法
WO1995019770A1 (en) *	1994-01-21	1995-07-27	Sepracor, Inc.	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US20030059471A1 (en) *	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
KR20030087048A (ko) *	2001-04-02	2003-11-12	아스트라제네카 아베	4-시아노-트리플루오로-3-(4-플루오로페닐설포닐)-2-히드록시-2-메틸프로피오노-ｍ 톨루이다이드 및 ｐｖｐ를포함하는 고체 약학 조성물
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103839D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product

2002
- 2002-02-22 DE DE60206889T patent/DE60206889T2/de not_active Expired - Fee Related
- 2002-02-22 HU HU0302847A patent/HUP0302847A3/hu unknown
- 2002-02-22 SK SK1072-2003A patent/SK10722003A3/sk unknown
- 2002-02-22 PL PL02365746A patent/PL365746A1/xx not_active Application Discontinuation
- 2002-02-22 RU RU2003128971/15A patent/RU2003128971A/ru not_active Application Discontinuation
- 2002-02-22 MX MXPA03007641A patent/MXPA03007641A/es unknown
- 2002-02-22 KR KR10-2003-7011178A patent/KR20030077042A/ko not_active Withdrawn
- 2002-02-22 CZ CZ20032225A patent/CZ20032225A3/cs unknown
- 2002-02-22 CA CA002439366A patent/CA2439366A1/en not_active Abandoned
- 2002-02-22 AT AT02712105T patent/ATE307571T1/de not_active IP Right Cessation
- 2002-02-22 EE EEP200300416A patent/EE200300416A/xx unknown
- 2002-02-22 EP EP02712105A patent/EP1368001B1/en not_active Expired - Lifetime
- 2002-02-22 JP JP2002567261A patent/JP3548566B2/ja not_active Expired - Fee Related
- 2002-02-22 US US10/468,276 patent/US20040067257A1/en not_active Abandoned
- 2002-02-22 WO PCT/GB2002/000766 patent/WO2002067893A2/en not_active Ceased
- 2002-02-22 IL IL15738902A patent/IL157389A0/xx unknown
- 2002-02-22 NZ NZ527532A patent/NZ527532A/xx unknown
- 2002-02-22 CN CNA028087356A patent/CN1503662A/zh active Pending
- 2002-02-26 UY UY27186A patent/UY27186A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100712A patent/AR032912A1/es not_active Application Discontinuation
2003
- 2003-08-15 IS IS6915A patent/IS6915A/is unknown
- 2003-08-26 NO NO20033785A patent/NO20033785L/no not_active Application Discontinuation
2004
- 2004-02-18 JP JP2004041583A patent/JP2004143185A/ja active Pending

Also Published As

Publication number	Publication date
HUP0302847A2 (hu)	2003-12-29
MXPA03007641A (es)	2003-12-04
SK10722003A3 (sk)	2004-02-03
DE60206889D1 (de)	2005-12-01
EE200300416A (et)	2003-12-15
JP2004521918A (ja)	2004-07-22
WO2002067893A2 (en)	2002-09-06
HUP0302847A3 (en)	2005-05-30
EP1368001B1 (en)	2005-10-26
EP1368001A2 (en)	2003-12-10
AR032912A1 (es)	2003-12-03
ATE307571T1 (de)	2005-11-15
NO20033785D0 (no)	2003-08-26
CN1503662A (zh)	2004-06-09
PL365746A1 (en)	2005-01-10
CA2439366A1 (en)	2002-09-06
WO2002067893A3 (en)	2003-01-16
IS6915A (is)	2003-08-15
JP2004143185A (ja)	2004-05-20
IL157389A0 (en)	2004-05-12
NZ527532A (en)	2004-12-24
US20040067257A1 (en)	2004-04-08
KR20030077042A (ko)	2003-09-29
CZ20032225A3 (cs)	2003-11-12
UY27186A1 (es)	2002-09-30
DE60206889T2 (de)	2006-07-27
JP3548566B2 (ja)	2004-07-28
RU2003128971A (ru)	2005-03-10

Publication	Publication Date	Title
NO20033384L (no)	2003-09-25	Farmasoytisk formulering
NO20033785D0 (no)	2003-08-26	Farmasöytisk formulering
NO20033556L (no)	2003-10-09	Farmasöytiske formuleringer
ITTO20010008A0 (it)	2001-01-10	Formulazione farmaceutica
FI20011478A0 (fi)	2001-07-05	Farmaseuttinen koostumus
PT1501534E (pt)	2006-09-29	Formulacoes farmaceuticas
PL367180A1 (pl)	2005-02-21	Trwała kompozycja farmaceutyczna
NO20035627D0 (no)	2003-12-15	Farmasöytisk formulering
EE200300589A (et)	2004-02-16	Ravimkoostised
FI20022128A0 (fi)	2002-12-03	Farmaseuttinen koostumus
NO20042502L (no)	2004-08-09	Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no)	2004-04-13	Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
NO20015534D0 (no)	2001-11-12	Farmasöytisk blandeapparat
EE200300465A (et)	2003-12-15	Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de)	2005-03-10	Pharmazeutische Zusammensetzung
NO20041236L (no)	2004-03-24	Farmasoytisk formulering
SE0101171D0 (sv)	2001-04-02	Pharmaceutical formulation
SE0102572D0 (sv)	2001-07-19	Pharmaceutical formulation
SE0102069D0 (sv)	2001-06-21	Pharmaceutical formulation
SE0101326D0 (sv)	2001-04-12	Pharmaceutical formulation
SE0103565D0 (sv)	2001-10-25	Pharmaceutical formulation
SE0101325D0 (sv)	2001-04-12	Pharmaceutical formulation
SE0102957D0 (sv)	2001-09-04	Pharmaceutical formulation
EP1413314A4 (en)	2004-12-22	MEDICAL COMPOSITIONS

Legal Events

Date	Code	Title	Description
2006-10-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application